Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail
Ashish Srinivasan, Peter De Cruz, Daniel R van Langenberg
Alimentary Pharmacology & Therapeutics | WILEY | Published : 2020
PDC is supported by a National Health & Medical Research Council (NH&MRC) Early Career Fellowship. AS is supported by an Australian Government Research Training Program (RTP) scholarship.